Hugh Lin

Hugh Lin, MD MBA, is the Vice President and Head of Ophthalmology at Genentech, where they lead the lifecycle of the ophthalmic treatment Vabysmo from 2022 to 2025. They previously held roles at Allergan as a Director of Clinical Development and served as a Physician at Pacific Eye Care Center. Hugh completed a Glaucoma Fellowship and worked as a Clinical Instructor at Stanford University Medical Center, and spent time as a Medical Intern in Internal Medicine at UCLA, Oliveview Medical Center. They have also held multiple leadership positions at Genentech from 2015 to 2019. Currently, Hugh is pursuing multiple advanced degrees, including a Doctor of Medicine (M.D.) and a Master of Business Administration (MBA) in Health Care Management.